On Wednesday, FS Investment Corporation (NYSE:FSIC)’s shares declined -0.49% to $10.21.
Zeta Interactive (Zeta), a big data and analytics company, which assists brands acquire, grow and retain customers, recently declared that it has closed a $125 million round of financing from FS Investment Corporation (FSIC), FS Investment Corporation II (FSIC II) and FS Investment Corporation III (FSIC III), business development companies (BDCs) advised by associates of Franklin Square Capital Partners (Franklin Square) and sub-advised by an associate of GSO Capital Partners LP (GSO), the credit platform of Blackstone (BX). Under the terms of the investment, these BDCs will provide up to $125 million in a mix of debt and equity.
Zeta will use the financing to enhance and expand its Gartner Magic-Quadrant-rated platform; grow its market penetration in the US and UK markets; and accelerate the company’s planned acquisition strategy. Zeta has been an active acquirer in the Data, Analytics and SaaS-based technology sectors. In the past two years, the company has attained the marketing automation platform pioneer, ClickSquared, and the Actions division of Adchemy Inc., together with its patented machine learning platform.
FS Investment Corporation is a business development company specializing in investments in debt securities. It seeks to purchase interests in loans through secondary market transactions or directly from the target companies as primary market investments. It also seeks to invest in first lien senior secured loans, second lien secured loans and, to a lesser extent, subordinated loans, or mezzanine loans. In connection with the debt investments, the firm also receives equity interests such as warrants or options as additional consideration.
Sorrento Therapeutics Inc (NASDAQ:SRNE)’s shares gained 1.58% to $24.36.
Sorrento Therapeutics, Inc. (SRNE) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, declared recently that Mr. George Uy, Executive Vice President and Chief Commercial Officer, will be leaving the Company at the end of July 2015 to join a start-up company as its Chief Executive Officer.
Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, counting the treatment of chronic cancer pain, in addition to developing therapeutic products for other indications, such as immunology and infectious diseases. Its lead product, Cynviloq, is polymeric, albumin-free nanoparticle paclitaxel formulation, approved and marketed in South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also accomplished Phase I, Phase II, and Phase III clinical trials, and post-marketing surveillance studies in MBC, NSCLC, ovarian, pancreatic, and bladder cancer.
At the end of Wednesday’s trade, Simon Property Group Inc (NYSE:SPG)‘s shares surged 0.34% to $182.38.
Simon, a leading global retail real estate company, declared that Gary M. Rodkin has been designated to its Board of Directors.
Mr. Rodkin has noteworthy administration and marketing expertise with over 30 years of extensive operating and brand-building experience, counting having served as Chief Executive Officer or President of public companies and as a director of other publicly held corporations in a variety of industries.
Simon Property Group, Inc. is an equity real estate investment trust. The firm invests in the real estate markets across the globe. It engages in investment, ownership, administration, and development of properties. It primarily invests in regional malls, premium outlets, mills, and community/lifestyle centers to create its portfolio. Simon Property Group, Inc. was founded in 1960 and is based in Indianapolis, Indiana, with additional office in New York, New York.
MedAssets, Inc. (NASDAQ:MDAS), ended its Wednesday’s trading session with 1.25% gain, and closed at $21.03.
MedAssets, Inc. (MDAS) declared that it plans to release its financial results for the second quarter and six-month period ended June 30, 2015 after 4:00 p.m. ET on Wednesday, July 29, 2015.
MedAssets, Inc., a performance improvement company, provides technology-enabled products and services for hospitals, health systems, non-acute healthcare providers, payers, and other service providers and product manufacturers in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
